TPO and neoplasm: There are data indicating that tumor invasion of the bone marrow, prior pelvic irradiation, prior temozolomide treatment, and higher baseline TPO levels are all predictors of non‐response to romiplostim, however, prediction of response to romiplostim remains subject to ongoing study.